Topic

Cancer

21
Jul
2015

The Non-Compete Chill Has Passed: Bristol-Myers, MedImmune Settle Over I-O Star

There’s good news today for the biotech labor market. AstraZeneca’s MedImmune biologics unit said today that David Berman has joined the company as a senior vice president and head of its Oncology Innovative Medicines unit (iMED). Berman spent the previous decade at Bristol-Myers Squibb, becoming a key player inside the company during its rise to prominence in the hot field...
Read More
17
Jul
2015

Forget Price Controls – Value-Based Pricing is the New Threat to Drug Development

Election season is here, and every day brings a parade of presidential hopefuls, staking out positions along the political spectrum.  And, if the early rhetoric is any indication, one of the defining themes of the election will be wealth and income disparity. In an interview with the Des Moines Register, Hillary Clinton said that, although she generally supported the Affordable...
Read More
15
Jun
2015

It’s Time to Re-Think Some Assumptions About Cancer R&D

This is a time to take a step back and re-think cancer treatment. The exciting new wave of immunotherapy is challenging many basic assumptions about the way cancer R&D gets done. It’s time to re-imagine some of the biology, how we measure success and failure, how investment dollars get spread, and how we ought to pay for the progress.
11
Jun
2015

NEA, Polaris Bet $22M on Startup, Xtuit, to Break Down Tumor Microenvironment

Logic would say cancer drugs can’t work if something is keeping them out of the tumor. The latest startup from the Bob Langer/Polaris Partners factory floor just got $22 million to clear out some of the barriers around tumors, and make it easier for some of the exciting new immuno-oncology drugs to do what they do best. Cambridge, Mass.-based Xtuit Pharmaceuticals,...
Read More
22
May
2015

The Genentech Alumni: Where Are They Now?

Genentech is almost 40 years old, and still has spring in its step. Through ups and downs, the company has never stopped attracting first-rate talent, and still develops people with the itch to do big things in healthcare. Last week, a trio of Genentech veterans came together to start a neuroscience company called Denali Therapeutics that raised initial financing of...
Read More
16
Apr
2015

AACR Conference Preview: Five Themes To Watch In Immunotherapy

This coming weekend is the annual American Association of Cancer Research (AACR) meeting in Philadelphia. This conference is known as a showcase for research in its early, exploratory stages, and occasionally as the place where late-stage, practice-changing clinical trial data get presented. I wanted to offer a preview of what to expect. Once again, immunotherapy promises to be a major...
Read More
6
Apr
2015

Baseball Meets Biotech, Where Hope Springs Eternal

Baseball season is here, and I can’t wait. It’s time to draw some analogies between these two passions of mine. Plenty of writers have observed that baseball is basically a microcosm of life in all its messy glory, filled with hope and disappointment. This time of year, the old saying goes, “hope springs eternal.” Fans are optimistic, and maybe even...
Read More
4
Apr
2015

Will We Just Give Up on Federal Funding for Research? I Sure Hope Not

Most people on the street have no idea where the money comes from to support basic research into diseases like cancer, Alzheimer’s, or diabetes. The issue only gets muddier when research centers complain about federal funding cuts, which sounds self-serving and whiny to many ordinary taxpayers This week, the folks at my local public radio station, KUOW in Seattle, asked...
Read More
25
Feb
2015

The Tularik Alumni: Where Are They Now?

Two of the biggest stories in biotech this week, Flexus Biosciences and NGM Biopharmaceuticals, had something in common. They were both led by entrepreneurs who cut their teeth years ago at Tularik. That company name from the past is dotted all over the employment histories of the people now running Flexus Biosciences and NGM Biopharmaceuticals. For those who missed it,...
Read More
11
Feb
2015

FAQs About the Timmerman Report

Questions and comments have been pouring in here at Timmerman Report headquarters ever since the site debuted on Feb. 2. The early days have been nothing short of spectacular in my view. I’ll have more to say about that shortly. But for now, there are some of answers to the questions that keep popping up: Q: What do you cover?
5
Feb
2015

Former Dendreon CEO Lures Ex-Amgen Scientists to Immunotherapy Startup

Dendreon is in bankruptcy, but the people who once worked at the trailblazer of cancer immunotherapy keep finding gainful new opportunities. Former Dendreon CEO Mitch Gold has a new company up and running with a couple of ex-Amgen scientists. The startup, Alpine Immune Sciences, has secured $1.3 million from Gold’s Alpine Bioventures investment vehicle. News of the funding was disclosed...
Read More